Synchron, a New York City-based medical technology company, has demonstrated the first thought-controlled iPad experience using Apple's new brain-computer interface (BCI) human interface device protocol. The technology employs Synchron's Stentrode brain implant, which allows users to control Apple devices solely through neural signals. This advancement was showcased in a demonstration involving an ALS patient who regained a degree of independence by operating an iPad with their thoughts. Synchron's BCI system is noted for being less invasive, more scalable, and more durable compared to other neural interface technologies such as Neuralink. The collaboration between Synchron and Apple marks a significant step toward integrating brain implants with consumer electronics, potentially benefiting individuals with complex neurological conditions.